New Class of Drugs for the Treatment of Advanced Lung Disease
Researchers have demonstrated the potential of a new class of drugs for the treatment of refractory chronic obstructive pulmonary disease, i.e. COPD. Incurable to date, the disease is one of the most frequent causes of death worldwide and is typically triggered by smoking. In the current preclinical study, two anti-inflammatory substances have proved more effective than preparations used to date. The results were published in the Journal of Allergy and Clinical Immunology.
The study was a cooperative effort between the team headed by assistant professor Dr Jürgen Knobloch from the Medical Clinic III for Pneumology, Sleep and Respiratory Medicine at the Bergmannsheil University Hospital in Bochum, Germany, and Prof Dr Andrea Koch, member of the German Center for Lung Research (DZL), previously in Bochum, now at the Medical Clinic V for Pneumology at the LMU University Hospital in Munich, as well as a team from the company RespiVert Ltd, a subsidiary of Janssen Biotech Inc., and Prof Dr Erich Stoelben from the Lung Clinic in Köln-Merheim. According to the authors of the study, the new substances may potentially constitute a breakthrough in the treatment of COPD.
New drug candidates reduce inflammation
COPD patients suffer from chronic inflammation of the respiratory tract. Certain enzymes, so-called protein kinases, regulate the inflammation process. They are indirectly over-activated due to smoking, due to pro-inflammatory factors characteristic of COPD, and due to respiratory infections. This results in the production of even more pro-inflammatory factors, which, in turns, promotes disease progression.
According to the researchers, Narrow Spectrum Kinase Inhibitors, i.e. NSKI, that inhibit protein kinases constitute a promising therapy approach. Two NSKIs - namely RV1088 und RV568, which were identified and provided by RespiVert for the studies - were tested by the team in cell cultures; the researchers compared their efficacy with a conventional corticosteroid and various Single Protein Kinase Inhibitors, which are likewise considered potential drug candidates. The NSKIs were more effective in decelerating the production of inflammatory agents than any of the reference substances.
Effect of other substances not sufficient
A number of small molecule inhibitors of specific single kinases have previously been successfully tested in preclinical trials and advanced to clinical studies. These substances selectively inhibit individual protein kinases or a family of protein kinases. "However, it is emerging that the effect would not be sufficient in clinical applications," explains Jürgen Knobloch, head of laboratory at the Pneumology Clinic at Bergmannsheil. "In case of such a specific inhibition, activation of other protein kinases may act to induce similar inflammation."
Therefore, the team tested new drug candidates that target not only one protein kinase or a family of protein kinases, but a specific spectrum of several protein kinase families. In the research lab at the Bergmannsheil Pneumology Clinic, researchers then tested the substances in primary cultures of airway smooth muscle cells taken from COPD patients.
Potentially transferable to clinical applications
"Our study has demonstrated that NSKIs are promising candidates for the development of urgently required anti-inflammatory COPD therapies," says Jürgen Knobloch. Consequently, he and his colleagues believe that the findings gained in the preclinical model offer an immense potential for a transfer to applications in patient care.
According to expert estimates, COPD currently affects 11.7 percent of the global population. In most cases, the disease starts as chronic bronchitis, and it is mainly caused by smoking tobacco. Current therapies can retard the progression of COPD and provide symptom relief, but they cannot stop it. With the exception of one drug that is used for the treatment of very severe COPD in a subset of the COPD population, there are currently no other approved non-steroidal therapies that target inflammation, which is central for the progression of COPD. Currently available inhaled corticosteroids help alleviate the symptoms of other chronic inflammatory pulmonary diseases and provide some benefit in the prevention of acute exacerbations, but they are currently only recommended for use in combination with bronchodilators and in patients that experience frequent exacerbations.
Clinical Studies in progress
The substances identified in this study are currently being developed further by a pharmaceutical company in a clinical programme, as part of a translational effort to bring these compounds forward for patients.
This article has been republished from materials provided by Ruhr-University Bochum. Note: material may have been edited for length and content. For further information, please contact the cited source.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 2 ADD COMMENT
Pamela wayans | May 07, 2018
I have had ASTHMA my whole life but about 7 years ago my asthma got so bad and was diagnosed of EMPHYSEMA/COPD which was most likely due to the asthma. I was on double antibiotics and steroids, still didn't feel any better. My lungs were constantly wheezing in all four chambers, i already used Advair, Spiriva, and Albuterol in my nebulizer, they just didn’t do much. April 2016 my sister in-law told us about Rich Herbs Foundation where she ordered herbs that effectively treated her arthritis. We ordered their COPD herbal treatment after reading alot of positive reviews, i am happy to report this COPD herbal treatment reversed my lungs condition. My quality of life has greatly improved and every one of my symptoms including difficulty breathing and wheezing are gone. Their official web page is ww w. richherbsfoundation. com. I will be 52 soon and have never been healthier!
Sorice Madina | Apr 29, 2018
I was diagnosed with Emphysema. My symptoms included shortness of breath, dizziness, lack of oxygen to all body parts, numbness of fingers, no energy, no appetite, fatigue, and bloodshot eyes. I was living at a place that has mold and mildew in the air conditioning unit. I also smoked a pack a day for 20 years. The Pulmonologist started me on Spiriva and Advair plus nose sprays, to reduce symptoms and slow down progression but I could not tolerate them for long due to severe side effects so I opted not to go on prescription medicines but decided on using herbs instead, October 18, 2017 after being on the herbs you recommended, i had a total recovery from Emphysema disease with this natural herbal formula treatment. The shortness of breath, dizziness has subsided. When I stumbled upon you guys, it was just pure instinct. And from that day on it has been one of the best decisions I’ve made in my life. The caring that goes into explaining what herbs work for whatever ails me is astounding. In today’s world where so many are after a quick buck, selling without care, Natural Herbal Garden’s staffs amplifies the difference. I’m a believer in karma, and for generations to come, this is a herbal store that will be leaving it’s footprint in this world. Visit NATURAL HERBAL GARDENS official web site www. naturalherbalgardens. com A world of thanks to The Natural Herbal Gardens!”
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018